Identification of a novel ligand for the ATAD2 bromodomain with selectivity over BRD4 through a fragment growing approach

DOI: 10.1039/C8OB00099A

Authors: Duncan C. Miller (Northern Institute for Cancer Research, Newcastle University) , Mathew P. Martin (Northern Institute for Cancer Research, Newcastle University) , Santosh Adhikari (Northern Institute for Cancer Research, Newcastle University) , Alfie Brennan (Northern Institute for Cancer Research, Newcastle University) , Jane A. Endicott (Northern Institute for Cancer Research, Newcastle University) , Bernard T. Golding (Northern Institute for Cancer Research, Newcastle University) , Ian R. Hardcastle (Northern Institute for Cancer Research, Newcastle University) , Amy Heptinstall (Northern Institute for Cancer Research, Newcastle University) , Stephen Hobson (Northern Institute for Cancer Research, Newcastle University) , Claire Jennings (Northern Institute for Cancer Research, Newcastle University) , Lauren Molyneux (Northern Institute for Cancer Research, Newcastle University) , Yvonne Ng (Northern Institute for Cancer Research, Newcastle University) , Stephen R. Wedge (Northern Institute for Cancer Research, Newcastle University) , Martin Noble (Northern Institute for Cancer Research, Newcastle University) , Celine Cano (Northern Institute for Cancer Research, Newcastle University)
Co-authored by industrial partner: No

Type: Journal Paper
Journal: Organic & Biomolecular Chemistry , VOL 21

State: Published (Approved)
Published: February 2018

Abstract: ATAD2 is an ATPase that is overexpressed in a variety of cancers and associated with a poor patient prognosis. This protein has been suggested to function as a cofactor for a range of transcription factors, including the proto-oncogene MYC and the androgen receptor. ATAD2 comprises an ATPase domain, implicated in chromatin remodelling, and a bromodomain which allows it to interact with acetylated histone tails. Dissection of the functional roles of these two domains would benefit from the availability of selective, cell-permeable pharmacological probes. An in silico evaluation of the 3D structures of various bromodomains suggested that developing small molecule ligands for the bromodomain of ATAD2 is likely to be challenging, although recent reports have shown that ATAD2 bromodomain ligands can be identified. We report a structure-guided fragment-based approach to identify lead compounds for ATAD2 bromodomain inhibitor development. Our findings indicate that the ATAD2 bromodomain can accommodate fragment hits (Mr < 200) that yield productive structure–activity relationships, and structure-guided design enabled the introduction of selectivity over BRD4.

Subject Areas: Biology and Bio-materials, Chemistry, Medicine


Instruments:

Added On: 26/02/2018 08:42

Documents:
C8OB00099A.pdf

Discipline Tags:

Non-Communicable Diseases Health & Wellbeing Cancer Biochemistry Chemistry Structural biology Organic Chemistry Drug Discovery Life Sciences & Biotech

Technical Tags:

Diffraction Macromolecular Crystallography (MX)